The retail market for therapeutic enteral nutrition in Russia maintains positive dynamics. In Q1 2026, total sales volume reached RUB 1.9 billion (at retail prices, including VAT), with 4.3 million packages or 1.1 thousand tons of the corresponding products sold. Compared to January–March 2025, consumer spending in the category increased by 13.2%, while physical demand grew by 5.2%. In total for 2025, 16.7 million packages of the analyzed products were sold on the market, with Russian spending exceeding RUB 7.2 billion. After a brief period of demand stagnation in 2023, due to a decline in physical sales of certain foreign products, the category has returned to stable growth. The key driver of the market is the e-commerce segment, which grew twice as fast as offline at the beginning of 2026, with online purchase dynamics recorded at +20.2% in monetary terms and +8.7% in physical terms. As a result, the overall share of online exceeded 38% of the market by revenue and 30% by physical volume of products sold.

The market remains highly import-dependent: the total share of products from the Netherlands and the USA exceeds 68% in monetary terms. In the structure of physical consumption, manufacturers from the USA hold the lead (59% in packages). The share of domestic products based on Q1 2026 reached nearly 11% in money and 14% in packages. In 2022, Russian therapeutic enteral nutrition accounted for only about 3.3% of the market. Amid the strengthening positions of local players, a reduction in the presence of a number of foreign brands is observed. The decline in share over recent years is particularly noticeable for products from France. While in 2022 they accounted for 10.3% of physical demand, in 2025 and the beginning of this year it was only about 6.5%. However, in terms of ruble sales indicators, their share is significantly higher, at 15.3%, although it is characterized by a downward trend.

The assortment of the retail therapeutic nutrition market in 2025 consisted of 52 brands and 370 SKUs, of which more than a quarter (over 100 items) are domestically produced products. The undisputed leader of the segment remains the brand Pediasure from Abbott, holding a share of more than 30% of the market's total revenue (including the e-commerce channel), although the brand's dynamics were restrained, with annual sales growth of only 4%. The highest ruble growth rate among all brands represented in retail was observed for the specialized therapeutic enteral nutrition line Frebini, developed specifically for children by the German company Fresenius — annual sales of the brand increased 52-fold.

The main contribution to the dynamics of domestic products is provided by Infaprim and Leovit Nutrio, whose sales in monetary terms increased by 25.4% and 40% in rubles, respectively. However, physical demand for Leovit Nutrio products decreased by 2.6% in packages over the year. Additionally, over the past two years, two more Russian manufacturers have appeared in the therapeutic nutrition category: Pharmalakt and ART Modern Scientific Technologies. The highest dynamics among domestic products within the TOP-20 in terms of monetary sales volume in Q1 2026 was shown by Bioshake from Pharmalakt (3-fold growth in rubles).

Fig. Structure of the Russian Retail Market for Therapeutic Enteral Nutrition (including pharmacies, marketplaces, and the FMCG segment) by Supplier Country in 2022–2025 and Based on Q1 2026 Results, % RUB